SCHEMBL18031885

SCHEMBL18031885

COc1cc(Br)c(F)c(C(C)=O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
MAPK1 P28482 3/20 0.44
HPGD P15428 3/20 0.44
CYP3A4 P08684 2/20 0.44
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTT P42858 2/20 0.39
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 2/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
MAOB P27338 1/20 0.36
MEN1 O00255 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SOS1 Q07889 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16069727 0.84 SOS1 (0.48) ALDH1A1HPGDCYP3A4HTTNPC1
SCHEMBL18000485 0.81 PLK1 (0.43) ALDH1A1HPGDNPC1RAB9AKMT2A
SCHEMBL30601557 0.79 CYP3A4 (0.50) ALDH1A1MAPK1HPGDCYP3A4USP2
SCHEMBL3922933 0.79 CYP3A4 (0.50) ALDH1A1MAPK1HPGDCYP3A4USP2
SCHEMBL4480739 0.78 ALDH1A1 (0.44) ALDH1A1MAPK1HPGDCYP3A4USP2
SCHEMBL21318895 0.76 ALDH1A1 (0.34) ALDH1A1HPGDCYP3A4USP2SMN1; SMN2
SCHEMBL1652968 0.76 ALDH1A1 (0.59) ALDH1A1MAPK1HPGDCYP3A4SMN1; SMN2
SCHEMBL7833873 0.74 CYP3A4 (0.51) ALDH1A1MAPK1HPGDCYP3A4USP2
SCHEMBL30601548 0.73 ALDH1A1 (0.67) ALDH1A1MAPK1HPGDCYP3A4HTT
SCHEMBL898467 0.73 ALDH1A1 (0.67) ALDH1A1MAPK1HPGDCYP3A4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170290839-A1 BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS INCYTE CORPORATION 2017-10-12 US disclosed
US-9708318-B2 Bicyclic heterocycles as FGFR4 inhibitors INCYTE CORPORATION (US) 2017-07-18 US disclosed
US-20160244449-A1 BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS INCYTE CORPORATION 2016-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290839-A1 BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS FGFR4, FGFR3, FGFR1 ALDH1A1 1368/4885MAPK1 2247/4885HPGD 1519/4885
US-20160244449-A1 BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS FGFR4, FGFR3, FGFR1 ALDH1A1 1368/4885MAPK1 2247/4885HPGD 1519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.